Skip to content

Research paper

Metabolic phenotypes and the gut microbiota in response to dietary resistant starch type 2 in normal-weight subjects: a randomized crossover trial

Scientific Reports
Q1
Mar 2019
Citations: 115
Influential: 3
Interventional (Human) Studies
84

Study answer

What this study found

Resistant starch type 2 had beneficial effects on abdominal adiposity and several metabolic and gut-related outcomes. Visceral fat area fell from 26.43 ± 2.63 cm2 to 21.70 ± 1.78 cm2 (p < 0.001) and subcutaneous fat area from 135.81 ± 10.57 cm2 to 127.33 ± 10.66 cm2 (p = 0.031). The intervention also increased 30 min insulin, 30 min C-peptide, active GLP-1, and serum acetate, while LDL-C decreased from 2.62 ± 0.11 to 2.57 ± 0.14; no adverse events were reported. The gut microbiota shifted, including an increase in Ruminococcaceae_UCG-005 and decreases in multiple other genera, supporting a…

Study & population
Randomized, double-blind, crossover trial in 19 healthy Chinese adults aged 18 to 55 years with BMI < 24 kg/m2.
Intervention
Participants received oral HAM-RS2 (resistant starch type 2) at a dose providing 40 g/day of resistant starch for 4 weeks, taken daily with three identical meals per day.
Key limitation
The trial was small, with only 19 completers, which limits precision and subgroup inference.
View sourceOpen PDF

Original abstract

No abstract is available for this paper.